Whalesbook
NPPA Ka Faisla: Chhote Price Hike Par Pharma Ki Fikra
Dekho bhai, National Pharmaceutical Pricing Authority (NPPA) ne essential medicines ki MRP (Maximum Retail Price) mein 0.64% tak ka increase allow kiya hai. Ye hike Wholesale Price Index (WPI) ke hisab se diya gaya hai, jo ki 0.64956% tha. Isse companies National List of Essential Medicines (NLEM) mein aane wali lagbhag 900 formulations jaise ki pain relievers, antibiotics ke prices thoda badha sakti hain. P Pichhle saal ye hike 1.74% tha aur 2023 mein sirf 0.0055%.
Cost Inflation Ka Attack, Price Hike Kaise Bachayega?
Pharma industry, jiska market value FY2023-24 mein $50 billion tha aur 2030 tak $130 billion hone ka target hai, abhi bohot pressure mein hai. Nifty Pharma index ka P/E ratio 33.9 hai. Companiyon ka kehna hai ki active pharmaceutical ingredients (APIs), solvents aur packaging ka kharcha 200% se 300% tak badh gaya hai. Global conflicts ki wajah se supply chain bigdi hui hai, jiski wajah se paracetamol API jaise raw materials ke prices double ho gaye hain. Is wajah se kai companies ne production bhi band kar diya hai. Analysts ka maanana hai ki FY2026 mein operating profit margins 24-25% ke aas paas reh sakte hain, par badhte kharchon se ye bhi mushkil ho sakta hai.
Limited Hike Se Kam Padega Kaam
Ye 0.64% ka price hike companies ke badhte expenses ko bilkul bhi cover nahi kar paayega. Global issues ki wajah se raw material prices 200-300% badh gaye hain, jisse profits par zabardast dabaav hai, especially choti companies ke liye. Price caps ki wajah se companies ko ya toh non-scheduled drugs par focus karna pad raha hai ya phir exports par, jahan US FDA jaise regulators ke strict rules aur global pricing ka alag tension hai. Ek parliamentary committee ne bhi NPPA ki oversight badhane ki baat kahi hai, jisse aur regulatory intervention ho sakta hai.
Aage Kya?
FY2026 ke liye analysts ka kehna hai ki Indian pharma sector ka revenue 7-9% grow karega, jisme domestic sales aur Europe exports ka yogdaan hoga. Operating margins 24-25% par stable rehne ki ummeed hai. Par ye sab high inflation aur global regulations ko manage karne par depend karega. Industry ka future growth quality aur innovation par depend karega, saath hi domestic price controls ko bhi follow karna hoga. Is situation mein woh companies zyada faayde mein reh sakti hain jinke paas alag-alag income sources hain ya jo NLEM mein na hone wale products par zyada focus karti hain.